Domov › Nevroblastom › New York
Klinične študije za Nevroblastom v New York
13 študij za Nevroblastom išče udeležence na lokacijah v New York.
Mesta v New York
Uradno besedilo študije (angleško)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Albany Medical Center, Albany
- Roswell Park Cancer Institute, Buffalo
- NYU Langone Hospital - Long Island, Mineola
- in še 7
Vključevanje udeležencevFaza 3
Do 30 let · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06172296A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
- Memorial Sloan Kettering Cancer Center, New York
Vključevanje udeležencevFaza 2Vabljeni zdravi prostovoljci
Vse starosti · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT04936529Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Memorial Sloan Kettering Cancer Center ( Site 1010), New York
- New York Medical College ( Site 1023), Valhalla
Vključevanje udeležencevFaza 1/2
6 Months – 25 Years · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT06395103N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
- Memorial Sloan Kettering Cancer Center, New York
Vključevanje udeležencevFaza 2
18 Months – 19 Years · Vsi spoli · Posodobljeno 28. avg. 2026 · NCT06528496Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Albany Medical Center, Albany
- Maimonides Medical Center, Brooklyn
- Roswell Park Cancer Institute, Buffalo
- in še 8
Vključevanje udeležencevFaza 3
365 Days – 30 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Vključevanje udeležencevFaza 1/2
12 Months – 30 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT04851119SPEARHEAD-3 Pediatric Study
- Memorial Sloan Kettering Kids, New York
Vključevanje udeležencevFaza 1/2
Starost 2–21 · Vsi spoli · Posodobljeno 11. avg. 2026 · NCT05642455A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
- Memorial Sloan Kettering Suffolk-Commack (Consent only), Commack
- Memorial Sloan Kettering Westchester (Consent only), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- in še 1
Vključevanje udeležencevFaza 2
Vse starosti · Vsi spoli · Posodobljeno 28. jul. 2026 · NCT06057948Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- Memorial Sloan Kettering Cancer Center, New York
Vključevanje udeležencevFaza 2
Starost 1 in več · Vsi spoli · Posodobljeno 29. maj 2026 · NCT00107289Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
- New York Medical College, Valhalla
Vključevanje udeležencevFaza 1
Starost 1–30 · Vsi spoli · Posodobljeno 15. apr. 2026 · NCT04308330Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
- Albert Einstein College of Medicine, Children's Hospital at Montefiore, The Bronx
- New York Medical Center/ Maria Fareri Children's Hospital, Valhalla
Vključevanje udeležencevFaza 2
Starost 1–50 · Vsi spoli · Posodobljeno 13. mar. 2026 · NCT01804634Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
- Memorial Sloan Kettering Cancer Center, New York
Vključevanje udeležencevOpazovalna študija
Vse starosti · Vsi spoli · Posodobljeno 15. okt. 2025 · NCT00588068A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- Children's Hospital at Montefiore, The Bronx
Vključevanje udeležencevFaza 2
18 Months – 40 Years · Vsi spoli · Posodobljeno 12. avg. 2025 · NCT05135975Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.